Prosecution Insights
Last updated: July 17, 2026
Application No. 19/433,491

HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS

Non-Final OA §102
Filed
Dec 26, 2025
Priority
Dec 30, 2023 — CN 202311858456.7 +4 more
Examiner
RAHMANI, NILOOFAR
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fujian Haixi Pharmaceuticals Co. Ltd.
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
1y 5m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
880 granted / 1136 resolved
+17.5% vs TC avg
Minimal -3% lift
Without
With
+-3.1%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
35 currently pending
Career history
1151
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
18.8%
-21.2% vs TC avg
§102
32.5%
-7.5% vs TC avg
§112
22.7%
-17.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1136 resolved cases

Office Action

§102
DETAILED ACTION Claims 30-56 are pending in the instant application. Applicant’s election of group (I), wherein W2 is C, W3 is C, W4 is C, W5 is C in the reply filed on 05/19/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). The requirement is still deemed proper and is therefore made FINAL. Claims 30-53, 55 in part wherein W2 is C, W3 is C, W4 is C, W5 is C are examined. Claims 54 and 56 and the remaining subject matter of claims 30-53, 55 are withdrawn per 37 CFR 1.142(b). 2. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 30-53, 55 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Chen et al., US 8030518. Chen et al. discloses the instant claimed compound, which from the STN search is PNG media_image1.png 244 778 media_image1.png Greyscale , PNG media_image2.png 232 794 media_image2.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Chen et al. 3. Claims 30-53, 55 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Follmann et al., US 20130131034. Follmann et al. discloses the instant claimed compound, which from the STN search is PNG media_image3.png 70 740 media_image3.png Greyscale PNG media_image4.png 210 352 media_image4.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Follmann et al. 4. Claims 30-53, 55 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Chen et al., US 9951019. Chen et al. discloses the instant claimed compound, which from the STN search is PNG media_image5.png 692 768 media_image5.png Greyscale , PNG media_image6.png 248 794 media_image6.png Greyscale , PNG media_image7.png 798 794 media_image7.png Greyscale , PNG media_image8.png 282 830 media_image8.png Greyscale , PNG media_image9.png 920 826 media_image9.png Greyscale , PNG media_image10.png 822 770 media_image10.png Greyscale , PNG media_image11.png 830 786 media_image11.png Greyscale , PNG media_image12.png 890 744 media_image12.png Greyscale , PNG media_image13.png 934 744 media_image13.png Greyscale , PNG media_image14.png 248 564 media_image14.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Chen et al. 5. Claims 30-53, 55 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Skerlj et al., WO 2017192841. Skerlj et al. discloses the instant claimed compound, which from the STN search is PNG media_image15.png 80 756 media_image15.png Greyscale PNG media_image16.png 170 484 media_image16.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Skerlj et al. 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /NILOOFAR RAHMANI/ 06/01/2026
Read full office action

Prosecution Timeline

Dec 26, 2025
Application Filed
Jun 04, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678444
SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
2y 5m to grant Granted Jul 14, 2026
Patent 12673936
ISOINDOLINONE COMPOUNDS, AND USES THEREOF
2y 7m to grant Granted Jul 07, 2026
Patent 12668594
TYK2 INHIBITORS AND USES THEREOF
3y 0m to grant Granted Jun 30, 2026
Patent 12655159
DEUTERATED IRAK DEGRADERS AND USES THEREOF
3y 6m to grant Granted Jun 16, 2026
Patent 12649742
CRYSTALLINE FORMS OF A PYRROLOPYRIDINE-ANILINE COMPOUND
2y 10m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
74%
With Interview (-3.1%)
1y 11m (~1y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1136 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month